Press release

Cencora Partners with WeInfuse to Bolster Infusion Strategy

Conshohocken, Pa. (March 20, 2024) Cencora, a global healthcare company, today announced a strategic partnership with WeInfuse, an infusion software provider, to bolster its infusion strategies. As part of the partnership, Cencora provided funding to accelerate WeInfuse’s development of its home infusion and specialty pharmacy software capabilities. 
 
Cencora’s infusion strategy was launched in 2022 with the purpose of helping hospitals and health systems with site of care optimization and alternate infusion site services – underpinning the growing importance of employing site of care strategies to prevent potential care gaps. Each phase of Cencora’s end-to-end solution aims to help health systems deploy and operate a clinically focused, sustainable infusion program for patients. 
 
Now paired with WeInfuse’s software, Cencora will further help customers confidently realize the benefit of an enterprise infusion strategy. Additionally, Cencora’s ordering system is integrated into WeInfuse’s software, adding management features that track inventory and offer analytics on infusion center operations. 
 
“Since the pandemic, the importance of standing up alternative infusion sites, including in the home, has grown at an unprecedented rate,” said Matt Glucksmann, SVP & President, Health Systems and Government Services at Cencora. “These programs are oftentimes complex to manage and require the right partners to make them successful. Our partnership with WeInfuse further guarantees the success of Cencora’s infusion strategy solution by simplifying the infusion pharmacy workflow, ensuring continuity of care and optimizing healthcare costs.”  
 
Welnfuse brings decades of hands-on experience in building and operating infusion centers and a deep passion for crafting solutions that reduce the complexities of site of care shifts. By using WeInfuse’s software, Cencora will empower its infusion provider customers to operate efficiently, decrease burnout, maximize profitability and help improve clinical outcomes. WeInfuse’s powerful, intuitive workflow features and robust reporting and analytics engine decrease confusion around the oftentimes complex infusion pharmacy process, giving operators more time to focus on patients.  
 
“Having owned and operated a chain of successful infusion centers, we have experienced firsthand the unique challenges of the infusion industry, down to its complex medication delivery model, inefficient processes and staff burnout,” said WeInfuse CEO Bryan Johnson. “With rising demand from patients for healthcare delivery in the home, as well as increasing site of care complexities, our partnership ensures that Cencora can operate its end-to-end infusion pharmacy solution efficiently, improving clinical outcomes in the process.” 
 
Cencora’s partnership with WeInfuse continues both organizations’ commitment to leadership and advocacy on behalf of home infusion providers across the United States. Both organizations are members of the National Home Infusion Association (NHIA), and Johnson, in addition to sitting on the Board of the Infusion Access Foundation (IAF), NICA's nonprofit patient advocacy organization, co-founded the National Infusion Center Association (NICA)  with WeInfuse COO Reece Norris.  
 
### 
 
About Cencora 
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at www.cencora.com
 
About WeInfuse 
Welnfuse is the premier technology and consulting provider for infusion therapy and medication delivery in the U.S., powering over 850 infusion centers across the country. Backed by decades of experience, Welnfuse consulting services guide clients through the dynamic infusion landscape. 
 
Welnfuse has expanded its software platform to include a complete home infusion and specialty pharmacy workflow. Welnfuse software helps organizations operate efficiently, maximize profitability, decrease burnout, and improve clinical outcomes. Its powerful, intuitive features for infusion workflows and a robust reporting and analytics engine help take the confusion out of infusion. To learn more, visit www.weinfuse.com.  

Press release

IntrinsiQ Specialty Solutions Expands Data Capabilities, Empowering Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

October 16, 2025

Media statement

Cencora to Support Commercial Launch of Precigen’s Novel Immunotherapy in the United States

September 24, 2025

Media mention

ThoughtSpot 2025 Highlights Cencora’s Commitment to Advancing the Future of Pharmacy and Ensuring Medication Access

August 27, 2025

Media contacts

Need help or have questions?  Send us a message and we'll get back to you soon.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.